Unveiling the Molecular Complexity of AML through Advanced Multi-Omics Analysis

The HemAtlas 2.0 project embarks on a groundbreaking multi-omics journey to unravel the complexities of pediatric acute myeloid leukemia (AML), incorporating a diverse range of pediatric cases including transient myeloproliferative disorder (TMD), myeloid leukemia of down syndrome (ML-DS) and AML defined by fusion oncogenes. Utilizing advanced techniques such as WES, RNA-seq, and ATAC-seq, aiming to decode AML's genetic and epigenetic complexity. Integrating multilateral data with clinical insights, our work advances AML subtype classification and elucidates the impact of somatic mutations on prognosis, particularly affecting overall and event-free survival. Through Multi-Omics Factor Analysis (MOFA), we uncover intricate molecular interactions that define AML's heterogeneity. This novel approach provides deep insights into AML's pathogenesis and identifies potential targets for therapy. Our findings underscore the benefits of multi-omics integration in enhancing disease understanding to improve classification and prognosis. The HemAtlas 2.0 project highlights the potential of combining diverse omic layers and clinical data to refine patient care strategies.

Publication History

Article published online:
09 May 2025